Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) major shareholder Healthcare Master Fun Broadfin bought 276,000 shares of the firm’s stock in a transaction on Monday, September 12th. The stock was acquired at an average cost of $1.66 per share, with a total value of $458,160.00. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Healthcare Master Fun Broadfin also recently made the following trade(s):

  • On Tuesday, September 13th, Healthcare Master Fun Broadfin bought 75,000 shares of Aegerion Pharmaceuticals stock. The stock was acquired at an average cost of $1.75 per share, with a total value of $131,250.00.

Shares of Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) opened at 1.78 on Monday. The stock’s 50 day moving average is $1.57 and its 200 day moving average is $2.44. Aegerion Pharmaceuticals Inc. has a 52-week low of $1.23 and a 52-week high of $18.27. The stock’s market cap is $52.53 million.

Aegerion Pharmaceuticals (NASDAQ:AEGR) last posted its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.34. Aegerion Pharmaceuticals had a negative return on equity of 128.77% and a negative net margin of 80.76%. The firm had revenue of $44.50 million for the quarter, compared to the consensus estimate of $35.50 million. On average, equities analysts predict that Aegerion Pharmaceuticals Inc. will post ($3.44) EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC increased its stake in shares of Aegerion Pharmaceuticals by 613.3% in the first quarter. Acadian Asset Management LLC now owns 110,564 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 95,064 shares during the last quarter. Ramsey Quantitative Systems increased its stake in shares of Aegerion Pharmaceuticals by 51.2% in the first quarter. Ramsey Quantitative Systems now owns 80,445 shares of the biopharmaceutical company’s stock worth $298,000 after buying an additional 27,231 shares during the last quarter. Spark Investment Management LLC increased its stake in shares of Aegerion Pharmaceuticals by 37.8% in the first quarter. Spark Investment Management LLC now owns 532,800 shares of the biopharmaceutical company’s stock worth $1,971,000 after buying an additional 146,200 shares during the last quarter. State Street Corp increased its stake in shares of Aegerion Pharmaceuticals by 2.6% in the first quarter. State Street Corp now owns 434,935 shares of the biopharmaceutical company’s stock worth $1,604,000 after buying an additional 11,077 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Aegerion Pharmaceuticals by 82.8% in the first quarter. Goldman Sachs Group Inc. now owns 294,691 shares of the biopharmaceutical company’s stock worth $1,090,000 after buying an additional 133,486 shares during the last quarter. 87.60% of the stock is currently owned by institutional investors and hedge funds.

Separately, Zacks Investment Research lowered Aegerion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 25th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $13.21.

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.

5 Day Chart for NASDAQ:AEGR

Receive News & Ratings for Aegerion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.